EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PTC Therapeutics's enterprise value is $2,200 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $839 Mil. Therefore, PTC Therapeutics's EV-to-EBITDA for today is 2.62.
The historical rank and industry rank for PTC Therapeutics's EV-to-EBITDA or its related term are showing as below:
PTCT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -106.67 Med: -9.38 Max: 3.42
Current: 2.62
During the past 13 years, the highest EV-to-EBITDA of PTC Therapeutics was 3.42. The lowest was -106.67. And the median was -9.38.
PTCT's EV-to-EBITDA is ranked better than 62.34% of 462
companies
in the Biotechnology industry
Industry Median: 10.24
vs PTCT: 2.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
PTC Therapeutics EV-to-EBITDA Historical Data
The historical data trend for PTC Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PTC Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, PTC Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's EV-to-EBITDA falls into.
PTC Therapeutics's current Enterprise Value is $2,200 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $839 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PTC Therapeutics's PE Ratio (TTM) for today is calculated as:
PTC Therapeutics's share price for today is $48.99.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of PTC Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTCT has been successfully added to your 